AstraZeneca is continuing to study AZD8205 as a monotherapy in dose optimization expansion cohorts of patients with ...

Cancer patients with wasting syndrome have gained weight after taking Pfizer’s anti-GDF-15 antibody in a midphase study, ...

Four years after launching a remote-controlled robotic laboratory in San Diego, Eli Lilly is shipping the operation overseas.

The FDA should be more open and collaborative to unleash a surge in approvals of rare disease drugs, according to a report by ...

Immune checkpoint inhibitors are the superheroes of cancer therapy. | Immune checkpoint inhibitors are the superheroes of ...

Atea has struggled to demonstrate bemnifosbuvir’s COVID potential in the past, including in a phase 2 trial back in the midst ...

The recent decision to merge Genentech’s two cancer departments was made for “scientific reasons,” executives explained to ...

Regeneron is back with long-term follow-up for its LAG-3 inhibitor and PD-1 inhibitor combo in advanced melanoma, phase 1 ...

Roche’s R&D is moving on up. The pharma giant has opened two new high-rises in Basel, Switzerland, according to a Sept. 10 ...

Medtronic is bringing on a new chief medical officer for its digital and robotics teams, who it described as one of the top ...

It’s an unusually busy Friday for biotech IPOs, with Zenas BioPharma, MBX and Bicara Therapeutics all going public with ...

Neurocrine Biosciences’ schizophrenia program pivot has failed. | Neurocrine Biosciences’ schizophrenia program pivot has ...